Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
77.2 EUR | -23.64% | +2.41% | +38.53% |
Jun. 24 | BioNTech, Duality Biologics Receive FDA Fast-Track Designation for Prostate Cancer Drug | MT |
Jun. 24 | BioNTech Cancer Treatment Gets US FDA Fast Track Designation | DJ |
Sales 2024 * | 2.75B 2.93B | Sales 2025 * | 2.74B 2.93B | Capitalization | 18.65B 19.93B |
---|---|---|---|---|---|
Net income 2024 * | -419M -448M | Net income 2025 * | -548M -586M | EV / Sales 2024 * | 2.18 x |
Net cash position 2024 * | 12.67B 13.55B | Net cash position 2025 * | 12.02B 12.85B | EV / Sales 2025 * | 2.42 x |
P/E ratio 2024 * |
-42.7
x | P/E ratio 2025 * |
-33.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.48% |
Latest transcript on BioNTech SE
Managers | Title | Age | Since |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 08-06-01 |
Özlem Türeci
FOU | Founder | 57 | 08-06-01 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 70 | 21-12-31 |
Director/Board Member | 67 | 08-06-01 | |
Helmut Jeggle
CHM | Chairman | 53 | 08-06-01 |
1st Jan change | Capi. | |
---|---|---|
+16.49% | 122B | |
+21.73% | 115B | |
+21.98% | 26.64B | |
-16.89% | 16.32B | |
-18.81% | 15.49B | |
-44.74% | 15.52B | |
+62.72% | 14.83B | |
+3.09% | 13.67B | |
+122.59% | 11.12B |